A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

Plasticity in programming of effector and memory CD8+T-cell formation

(2015) Ramon Arens et al.   IMMUNOLOGICAL REVIEWS

Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma

(2013) Sagar Lonial et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

(2013) Benjamin M. Cherry et al.   LEUKEMIA & LYMPHOMA

Immunomodulatory drugs in multiple myeloma

(2013) Swati Andhavarapu et al.   Expert Review of Hematology

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma

(2012) Jooeun Bae et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

(2012) Sergio Rutella et al.   Clinical & Developmental Immunology

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

(2012) J. Bae et al.   CLINICAL CANCER RESEARCH

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease

(2012) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

(2012) Kimberly Noonan et al.   CLINICAL CANCER RESEARCH

Immunotherapy of Cancer with 4-1BB

(2012) D. S. Vinay et al.   MOLECULAR CANCER THERAPEUTICS

Redefining myeloma

(2012) S. Vincent Rajkumar et al.   Nature Reviews Clinical Oncology

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

(2012) Caroline Rousseau et al.   TUMOR BIOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

(2011) N. Korde et al.   BLOOD

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders

(2011) Jooeun Bae et al.   BRITISH JOURNAL OF HAEMATOLOGY

Monoclonal antibodies in the treatment of multiple myeloma

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vaccines for Colorectal Cancer and Renal Cell Carcinoma

(2011) Katherine Kabaker et al.   CANCER JOURNAL

Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures

(2011) Niels Junker et al.   CELLULAR IMMUNOLOGY

Vaccination Strategies in Lymphomas and Leukaemias

(2011) Katayoun Rezvani et al.   DRUGS

Keeping STATs on Memory CD8+ T Cells

(2011) Janelle A. Olson et al.   IMMUNITY

Opposing Signals from the Bcl6 Transcription Factor and the Interleukin-2 Receptor Generate T Helper 1 Central and Effector Memory Cells

(2011) Marion Pepper et al.   IMMUNITY

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

(2011) J Bae et al.   LEUKEMIA

Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?

(2011) M. Tucci et al.   ONCOLOGIST

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

(2010) I. Papandreou et al.   BLOOD

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study

(2010) Martin Hjorth et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2009) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients

(2009) Klaudia Kuranda et al.   EXPERIMENTAL HEMATOLOGY

Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses

(2009) Axel Kallies et al.   IMMUNITY

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

(2009) Luca Gattinoni et al.   NATURE MEDICINE

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

(2008) B. Barlogie et al.   BLOOD

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH

Ag-Specific Type 1 CD8 Effector Cells Enhance Methotrexate-Mediated Antitumor Responses by Modulating Endogenous CD49b-Expressing CD4 and CD8 T Effector Cell Subpopulations Producing IL-10

(2008) Mark J. Dobrzanski et al.   IMMUNOLOGICAL INVESTIGATIONS